Repligen (NASDAQ:RGEN) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Repligen (NASDAQ:RGEN) released its quarterly earnings results on Thursday. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03, Zacks reports. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Repligen updated its FY 2025 guidance to 1.670-1.760 EPS.

Repligen Stock Performance

NASDAQ:RGEN opened at $158.99 on Friday. The stock’s 50 day simple moving average is $155.22 and its 200-day simple moving average is $148.79. Repligen has a 12-month low of $113.50 and a 12-month high of $203.13. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday. Wolfe Research began coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating on the stock. TD Cowen began coverage on shares of Repligen in a research report on Monday, February 10th. They issued a “buy” rating and a $200.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $180.00 price objective on shares of Repligen in a research note on Friday. Finally, Canaccord Genuity Group began coverage on shares of Repligen in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $183.36.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.